










- Stabilizace karbenů komplexy kovu (Ru, Rh): unikátní reaktivita




stabilizovaný karben
(stabilní, komerčně dostupný)






- syntéza (substituovaných) aryl sloučenin
- tolerance široké škály funkčních skupin




- metodologie vhodná i pro přípravu stericky stíněných systémů






- syntéza (substituovaných) aryl sloučenin





losartan (cca. 1000 kg/rok)
2011: > 1,5 mld. USD/rok







- flexibilní záměna halogenů (hetero)aryly



SCH 727965 (dinaciclib)
 CDK2 IC_{50} = 0.001 μ M
 CHK1 IC_{50} = 25 μ M
 Phase III clinical trials




SCH 900776
 CDK2 IC_{50} = 0.16 μ M
 CHK1 IC_{50} = 0.003 μ M
 Phase I/II clinical trials







R^3	CHK1 IC_{50} (nM)
	4500
	820
	280
	60




- flexibilní záměna halogenů (hetero)aryly
- metodologie vhodná i pro přípravu stericky stíněných systémů



R^6				
CHK1 IC_{50} (nM)	560	340	160	100
CDK2 IC_{50} (nM)	8300	2300	2200	22000



- tolerance široké škály funkčních skupin



epothilon C

- stabilizace mikrotubulů
- zastavení cyklu dělení buněk
- protinádorový účinek

